Search Results

You are looking at 31 - 40 of 299 items for :

Clear All
Full access

Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Ammar Ashfaq, Qian Zhang and Mishal Shaukat

Background: Multiple Myeloma(MM) has a variable response rate to different chemotherapies. We sought to determine Elotuzumab efficacy by assessing 50%, 90%, and 100% decrease in the M protein levels termed as partial response (PR), very good

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Robert L. Schlossman, Teru Hideshima, Dharminder Chauhan, Nicole A. Carreau, Irene M. Ghobrial, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson and Paul G. Richardson

Cancer ; 2008 : 200 – 213 . 2 Jemal A Siegel R Ward E . Cancer Statistics, 2009 . CA Cancer J Clin 2009 ; 59 : 225 – 249 . 3 Kumar SK Rajkumar SV Dispenzieri A . Improved survival in multiple myeloma and the impact of novel

Full access

Shaji K. Kumar

Shaji K. Kumar, MD, Professor of Medicine, Mayo Clinic Cancer Center, reviewed the significant changes in the therapeutic options and understanding of the biology of multiple myeloma (MM) at the NCCN 22nd Annual Conference. “The first step in

Full access

Paul G. Richardson, Teru Hideshima, Constantine Mitsiades and Kenneth C. Anderson

This paper was supported in part by grants: NIH SPORE IP50 CA10070-01, P0-1 78378, and R0-1 50947; the Doris Duke Distinguished Clinical Research Scientist Award; and the Cure for Myeloma Research Fund. Dr. Richardson receives research support

Full access

Mohamad A. Hussein

. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party . J Clin Oncol 2005 ; 23 : 9219

Full access

Kenneth Anderson

Studies reported in 2013 can help clinicians better manage multiple myeloma, while anticipating even better treatments and outcomes after drugs currently in the pipeline become available, according to Kenneth Anderson, MD, Kraft Family Professor

Full access

Yvonne A. Efebera and Nina Shah

Continuous Therapy Offers Survival Advantage, But Questions Remain In the past 5 years alone, 6 drugs have been FDA-approved for the treatment of multiple myeloma (MM). Despite significant improvements in progression-free survival (PFS) and overall

Full access

William I. Bensinger

): 186 – 190 . 2 Gahrton G Svensson H Björkstrand B . Syngeneic transplantation in multiple myeloma — a case-matched comparison with autologous and allogeneic

Full access

Huntsman Cancer Institute at the University of Utah

Multiple myeloma will account for an estimated 16,570 new cancer cases in the United States in 2006, with an estimated 11,310 deaths. It is not currently considered curable; however, treatment has evolved rapidly because of new drugs such as bortezomib, thalidomide, and lenalidomide. In addition, increased understanding of the bone marrow microenvironment is creating rationale for new combinations and new drug development. Important updates in the 2007 NCCN guidelines include new recommended single-agent and combination regimens for consideration for induction and salvage therapy.

For the most recent version of the guidelines, please visit

Full access

Jean-Luc Harousseau and Philippe Moreau

. Attal M Harousseau JL Stoppa AM . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome . N Engl J Med 1996 ; 335 : 91 – 97 . 2. Child JA Morgan GJ